1
Clinical Trials associated with 4-component Strep A Vaccine(GSK)A Phase 1 Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Vaccine Against Group A Streptococcus Pyogenes (Strep A) With Alum or AS37 in Healthy Adults 18 to 25 Years of Age in Australia
The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant. The Strep A vaccine will be tested for the first time in humans, in healthy young adults 18 to 25 years of age. The study will also assess if the vaccines have any immediate reactions and if they induce an immune response. A low, medium, and high dose of each formulation of the vaccine will be assessed in sequence.
100 Clinical Results associated with 4-component Strep A Vaccine(GSK)
100 Translational Medicine associated with 4-component Strep A Vaccine(GSK)
100 Patents (Medical) associated with 4-component Strep A Vaccine(GSK)
100 Deals associated with 4-component Strep A Vaccine(GSK)